Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Dermis-fat grafts and enucleation in Ghanaian children: 5 years' experience.

Essuman VA., Tagoe NN., Ndanu TA., Ntim-Amponsah CT.

Case Report / Series with a reported sample of 10 on Face & Skin, published in Ghana Med J (2014) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Ghana Med J (2014)
Country
Ghana
Reported sample size
10
Source database
PubMed
PMID
25709135
DOI
10.4314/gmj.v48i4.6

Abstract (original English)

Enucleation in young children often results in retarded orbital growth ipsilaterally. The need for an implant that will naturally grow with the child, like Dermis-fat Graft (DFG), for managing the anophthalmia has been of interest over the years. To evaluate the use of DFG as an implant for volume replacement post-enucleation. A prospective non-comparative case series involving 18 consecutive children who had DFG either primarily or secondarily in conjunction with enucleation for intraocular pathologies, from December 2007 to September 2012, at the ophthalmology unit, Korle-Bu. Data from patients who had a minimum of three months follow up(FUP) were analysed. Complete covering of DFG with healthy conjunctiva, increase in volume of DFG, and presence or absence of complications. Fifteen patients were analysed, aged nine months to ten years (mean (SD), 3.7±2.7years). Eight (53.3%) were females. Thirteen (86.7%) DFGs were secondary and 2(13.3%) primary. Indications for enucleation were intraocular retinoblastoma (n=10, 66.7%), unexplained retinal detachment mimicking retinoblastoma (n=3,20.0%), anterior staphyloma (n=1,6.7%) and medulloepithelioma (n=1,6.7%). Fourteen (93.3%) patients showed increase in volume of DFG. Time for Conjunctival reepithelialisation of the dermal surface was four to fourteen weeks (mean/median=5.5/4.0). Complications encountered were infection (n=1,6.7%),

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueChildChild, PreschoolConjunctivaCystsEye EnucleationEye NeoplasmsFemaleFollow-Up StudiesGhana

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research